^
14d
Enrollment closed
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • ociperlimab (BGB-A1217) • LBL-007
17d
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab (clinicaltrials.gov)
P1/2, N=53, Completed, BeiGene | Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> Aug 2024
Trial completion • Trial completion date
|
PD-L1 (Programmed death ligand 1)
|
Rituxan (rituximab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
2ms
Trial completion
|
PD-L1 (Programmed death ligand 1)
|
Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
2ms
AdvanTIG-302: A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer (clinicaltrials.gov)
P3, N=662, Active, not recruiting, BeiGene | Trial completion date: Oct 2026 --> Feb 2027 | Trial primary completion date: Apr 2026 --> Oct 2026
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
2ms
Trial completion • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
4ms
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Rituxan (rituximab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
6ms
Enrollment closed • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
6ms
Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
6ms
BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
P3, N=300, Enrolling by invitation, BeiGene | Trial completion date: Aug 2024 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Dec 2026
Trial completion date • Trial primary completion date • Metastases
|
temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • zanidatamab (ZW25) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445 • LBL-007 • surzebiclimab (BGB-A425)
7ms
Trial completion
|
PD-L1 (Programmed death ligand 1)
|
Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
8ms
Structural insights into the unique pH-responsive characteristics of the anti-TIGIT therapeutic antibody Ociperlimab. (PubMed, Structure)
TIGIT is mainly expressed on T cells and is an inhibitory checkpoint receptor that binds to its ligand PVR in the tumor microenvironment. In contrast, Tiragolumab does not show an acidic pH-dependent binding enhancement. Our results provide valuable information that could help to improve the efficacy of therapeutic antibodies for cancer treatment.
Journal
|
TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
ociperlimab (BGB-A1217) • tiragolumab (RG6058)
8ms
Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) in 1L PD-L1+ non-small cell lung cancer (NSCLC) (AACR 2024)
Anti-TIGIT MOA-related genes and signatures correlated with efficacy in ociperlimab + tislelizumab-treated 1L PD-L1+ NSCLC. Combining anti-TIGIT MOA-related factors with PD-L1 expression identified a subgroup of patients with improved efficacy.Table. Efficacy Analyses in Patient SubgroupsCutoff: aTop 1/3; bMedian; cTC≥25%
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CCR8 (C-C Motif Chemokine Receptor 8) • CD226 (CD226 Molecule)
|
PD-L1 expression • TIGIT expression
|
VENTANA PD-L1 (SP263) Assay
|
Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
9ms
AdvanTIG-302: A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer (clinicaltrials.gov)
P3, N=660, Recruiting, BeiGene | Trial completion date: May 2025 --> Oct 2026 | Trial primary completion date: Jan 2025 --> Apr 2026
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
9ms
AdvanTIG-105: Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=449, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | Trial primary completion date: May 2024 --> Aug 2024
Enrollment closed • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • capecitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • etoposide IV • ociperlimab (BGB-A1217)
9ms
Trial completion
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)
10ms
BGB-A317-A1217-301: A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=63, Terminated, BeiGene | Trial completion date: Jul 2027 --> Oct 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2027 --> Oct 2023; This decision was conducted by the sponsor and not driven by safety concerns as no new safety signals have been observed in the ociperlimab program.
Trial completion date • Trial termination • Trial primary completion date • Metastases
|
Imfinzi (durvalumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
10ms
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
11ms
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • capecitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • etoposide IV • ociperlimab (BGB-A1217)
11ms
Enrollment change • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • ociperlimab (BGB-A1217) • LBL-007
1year
Phase classification • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Rituxan (rituximab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
1year
Trial completion • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
1year
AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors. (PubMed, J Immunother Cancer)
Ociperlimab plus tislelizumab was well tolerated in patients with advanced solid tumors, and preliminary antitumor activity was observed with 450 mg, 900 mg, and 1800 mg ociperlimab. Phase II/III trials of ociperlimab 900 mg plus tislelizumab 200 mg Q3W are underway in a range of solid tumors.
P1 data • Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
|
TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
1year
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
1year
Enrollment closed • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
1year
AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab + Tislelizumab in Patients With Checkpoint Inhibitor (CPI)-Experienced Advanced Non-Small Cell Lung Cancer (NSCLC) (COSA 2023)
Ociperlimab 900mg + tislelizumab 200mg was generally well-tolerated and showed preliminary antitumor activity in patients with locally advanced/metastatic CPI-experienced NSCLC.
Clinical • P1 data • Checkpoint inhibition • Metastases
|
TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
1year
AdvanTIG-206: A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC (clinicaltrials.gov)
P2, N=90, Active, not recruiting, BeiGene | Trial completion date: Aug 2023 --> Mar 2024 | Trial primary completion date: Aug 2023 --> Mar 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)
1year
AdvanTIG-205: Ociperlimab With Tislelizumab and Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=272, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2024 --> Jul 2024
Enrollment closed • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
1year
Enrollment closed • Enrollment change • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
PD-L1 expression • TIGIT expression
|
Imfinzi (durvalumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
1year
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab (clinicaltrials.gov)
P1b/2, N=80, Recruiting, BeiGene | Trial completion date: Oct 2024 --> Feb 2025 | Trial primary completion date: Aug 2024 --> Nov 2024
Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Rituxan (rituximab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
over1year
Advantig-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (CT) in patients (pts) with metastatic oesophageal squamous cell carcinoma (ESCC) and oesophageal adenocarcinoma (EAC) (ESMO 2023)
Pts received the RP2D of OCI + TIS with cisplatin + 5-fluorouracil/paclitaxel until disease progression, intolerable toxicity, or consent withdrawal. C7 had too few pts for biomarker subgroup analysis. Table: 1533P Efficacy and Safety Summary Conclusions These results demonstrate that OCI 900 mg + TIS 200 mg + CT had a safety profile consistent with previous reports and showed encouraging antitumor activity in pts with stage IV ESCC and EAC.
Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
PD-L1 expression
|
cisplatin • paclitaxel • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
over1year
AdvanTIG-202: Phase II randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC) (ESMO 2023)
DoR, duration of response; IRC, independent review committee; m, median; mo, months; NE, not estimable; ORR, objective response rate; OS, overall survival; PFS, progression-free survival. . Conclusions OCI + TIS showed promising antitumor activity and durable responses, regardless of PD-L1 expression, and was well tolerated in pts with previously treated R/M CC.
Clinical • P2 data • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
over1year
AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity (ESMO 2023)
Table: 1020MO Efficacy O+T (n=62) P+T (n=63) ORRa, % (95% CI) INV b 30.6 (19.6, 43.7) 20.6 (11.5, 32.7) P c,d =0.2114 IRC e 32.3 (20.9, 45.3) 25.4 (15.3, 37.9) P c,d =0.4209 OS e,f (months), median (95% CI) 10.1 (7.1, NE) 9.3 (6.0, NE) HRc (95% CI): 0.93 (0.55, 1.58) P c,g =0.3977 PFS e (months), median (95% CI) INV 3.4 (1.8, 5.1) 3.5 (1.9, 4.1) HRc (95% CI): 0.93 (0.61, 1.43) IRC 3.6 (2.7, 5.1) 2.8 (1.9, 6.9) HRc (95% CI): 1.01 (0.64, 1.59) Median follow-up was 7 months. IRC, independent review committee; NE, not estimable aConfirmed per RECIST v1.1bPrimary endpoint cStratified d2-sided; by Cochran-Mantel-Haenszel method eSecondary endpoint fStill immature (event rate 45.6%) g1-sided; by log-rank test Conclusions In 2L therapy of advanced ESCC pts with PD-L1 TAP ≥10%, O+T showed tolerable safety profile and trend toward better ORR, but similar PFS vs. P+T.
Clinical • P2 data • Metastases
|
PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
over1year
Clinical • P2 data • Metastases
|
TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
Tevimbra (tislelizumab-jsgr) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)
over1year
Enrollment change • Trial withdrawal • Combination therapy • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed • ociperlimab (BGB-A1217)
over1year
Combination therapy • Enrollment change • Trial withdrawal • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • carboplatin • gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • ociperlimab (BGB-A1217)
over1year
Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)
over1year
Trial completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
over1year
Combination therapy • New P2 trial • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • carboplatin • gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • ociperlimab (BGB-A1217)
over1year
New P3 trial • Combination therapy • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed • ociperlimab (BGB-A1217)
over1year
Trial completion date • Trial primary completion date • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
PD-L1 expression
|
Imfinzi (durvalumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
over1year
Enrollment open
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217) • LBL-007